Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Clinical trial NCT05382286 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05382286
- Sponsor
- Gilead Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-25
- Primary completion
- 2027-02-01
- Enrollment
- 443
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.